[46] The study also showed that CRVO treatment with an anti-VEGF agent used on a monthly basis for 6 months followed by PRN produces significantly better results in all end points compared with sham.

Central retinal vein occlusion (CRVO) is a common retinal vascular disorder with potential risk of blindness. CRVO can be categorized into two distinct entities – non-ischemic and ischemic.